Clinical trials: Stage IV Melanoma
Kidney Cancer, Melanoma (Skin)
High-Dose Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer or Melanoma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells. Interleukin-2 may stimulate a person's white blood cells to kill kidney cancer or melanoma cells.
- Trial name
- NCT00003091
- Testing
- aldesleukin, recombinant interferon alfa
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Malignant Melanoma
GM-CSF as Adjuvant Therapy of Melanoma
This is a pilot study to describe the immunological responses and clinical outcome associated with administration of recombinant human Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) as surgical adjuvant therapy in…
- Trial name
- NCT00350597
- Testing
- Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Northern California Melanoma Center
Recurrent Melanoma, Stage IV Melanoma
Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases
This phase I trial studies the best dose of vemurafenib when combined with whole brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS) in patients with v-raf murine sarcoma viral oncogene homolog B (BRAF)…
- Conditions
- Recurrent Melanoma, Stage IV Melanoma, Tumors Metastatic to Brain
- Trial name
- NCT02145910
- Testing
- Vemurafenib, Whole-brain radiation therapy (WBRT), Radiosurgery (SRS)
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Metastatic, Stage III or Stage IV, Melanoma
Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Following Cyclophosphamide And Fludarabine In Patients With Melanoma
This is a phase II clinical study for patients with metastatic (the cancer has spread to other parts of the body) melanoma. Patients will receive an infusion (given by vein) of autologous tumor infiltrating lymphocytes (TILs).
- Trial name
- NCT01883323
- Testing
- Cyclophosphamide, Fludarabine, Tumor-Infiltrating Lymphocytes
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- University Health Network, Toronto
Malignant Melanoma
Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
This is a Phase I, open-label, multicenter, pharmacokinetic study of MDX-010 in up to 90 evaluable subjects with surgically unresectable malignant melanoma.
- Trial name
- NCT00729950
- Testing
- MDX-010
- Where
- 4 sites in United States
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Melanoma
A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes
To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have…
- Trial name
- NCT03526185
- Testing
- Tumor Infiltrating Lymphocytes, Nivolumab and Ipilimumab
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Yale University
Melanoma
PET-CT in the Management of Patients With Stage III or IV Metastatic Melanoma
The goal of this clinical research study is to learn how often using a positron emission tomography-computed tomography (PET-CT) scan in addition to a standard computed tomography (CT) scan will change the surgical plan in…
- Trial name
- NCT00828126
- Testing
- PET-CT Scan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Anxiety Disorder, Worry
Cognitive-Behavioral Intervention for Worry, Uncertainty, and Insomnia for Cancer Survivors
This randomized clinical trial studies a cognitive-behavioral intervention to treat worry, uncertainty, and insomnia in cancer survivors.
- Conditions
- Anxiety Disorder, Worry, Uncertainty, Sleep Disorders
- Trial name
- FOCUS (NCT01929720)
- Testing
- Cognitive-behavioral therapy for worry, uncertainty & insomnia
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Recurrent Melanoma, Stage IV Melanoma
Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Stage IV Melanoma
RATIONALE: Biological therapies, such as therapeutic autologous lymphocytes, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00438984
- Testing
- cyclophosphamide, therapeutic autologous lymphocytes, aldesleukin
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Melanoma
Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma
This is open label, single arm study for pts with stage IIIB-IV melanoma, accordingly with AJCC staging criteria (8th ed.), with potentially resectable disease.
- Trial name
- NCT06566391
- Testing
- Ipilimumab
- Where
- Italy
- Volunteers
- 35 people
- Sponsor
- European Institute of Oncology
Stage IV Melanoma
Investigating Participation Patterns Among Stage IV Melanoma Patients
Clinical trials, specifically focused on stage IV melanoma, are crucial in assessing the safety and efficacy of new treatments for this disease.
- Trial name
- NCT06093594
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Melanoma
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Treatment of subjects who have metastatic melanoma that expresses an activated mutant form of the BRAF oncogene (V600E) with a combination of the specific BRAF inhibitor, Vemurafenib, and the Cytotoxic T Lymphocyte Antigen 4…
- Trial name
- NCT01400451
- Testing
- Ipilimumab (BMS-734016), Vemurafenib
- Where
- 4 sites in United States
- Volunteers
- 18 people
- Sponsor
- Bristol-Myers Squibb
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Bone Loss in Melanoma Survivors Receiving Immunotherapy
This study investigates the bone-related side effects caused by immunotherapy drugs such as nivolumab and pembrolizumab in patients with melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Pathologic Stage III Cutaneous Melanoma AJCC v8, Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
- Trial name
- NCT04516122
- Testing
- Biospecimen Collection, Dual X-ray Absorptiometry
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells.
- Trial name
- NCT00436930
- Testing
- autologous tumor cell vaccine, sargramostim, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Hoag Memorial Hospital Presbyterian
Melanoma
Lenalidomide and Dacarbazine (DTIC) in Patients With Metastatic Melanoma
Primary Objectives: 1. To determine the maximum tolerated dose (MTD) of intravenous DTIC during the first 2 cycles (6 weeks) of treatment when administered in combination with a fixed dose of oral Lenalidomide in patients with…
- Trial name
- NCT00412581
- Testing
- Lenalidomide, Dacarbazine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma.
- Conditions
- Clinical Stage III Cutaneous Melanoma AJCC v8, Stage IV Melanoma, Unresectable Stage III Cutaneous Melanoma, Unresectable Stage IV Cutaneous Melanoma
- Trial name
- NCT04356729
- Testing
- Atezolizumab, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- F. Stephen Hodi, MD
Melanoma
A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma
The subsequent treatment choices for the patients with advanced melanoma, who have failed the immune checkpoint inhibitor therapy of single agent. Evidences showed that PD-1 and PD-L1 signalling pathways are not redundant.
- Trial name
- NCT04756934
- Testing
- HX008, LP002
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Taizhou HoudeAoke Biomedical Co., Ltd.
Malignant Melanoma
An Observational Study of BRAF Inhibitors Effectiveness in Patients With Newly Diagnosed Metastatic Melanoma
This observational study will evaluate the effectiveness of BRAF inhibitors and current therapies in patients with newly diagnosed metastatic melanoma with or without BRAF V600 mutation.
- Trial name
- NCT02143999
- Where
- 24 sites in Italy
- Volunteers
- 403 people
- Sponsor
- Hoffmann-La Roche
Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm
Acceptance and Commitment Therapy in Improving Well-Being in Patients With Stage III-IV Cancer and Their Partners
This pilot clinical trial studies how well acceptance and commitment therapy works in improving well-being in patients with stage III-IV cancer and their partners.
- Conditions
- Malignant Female Reproductive System Neoplasm, Malignant Hepatobiliary Neoplasm, Partner, Stage III Breast Cancer
- Trial name
- NCT03112668
- Testing
- Cognitive Behavior Therapy, Quality-of-Life Assessment, Questionnaire Administration
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Malignant Skin Melanoma T0, Stage III Melanoma
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.
NILOMEL is a phase II multicentric uncontrolled open national trial assessing the efficacy of Nilotinib in first or second line treatment of primary melanomas , stage III unresectable melanomas, or Stage IV melanomas with c-KIT…
- Conditions
- Malignant Skin Melanoma T0, Stage III Melanoma, Stage IV Melanoma, Amplification
- Trial name
- NILOMEL (NCT01168050)
- Testing
- Nilotinib
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.